Analysts Set Repligen Co. (NASDAQ:RGEN) Price Target at $190.25

Shares of Repligen Co. (NASDAQ:RGEN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $190.25.

RGEN has been the topic of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research note on Wednesday, July 31st. UBS Group reduced their price objective on Repligen from $205.00 to $185.00 and set a "buy" rating on the stock in a research note on Wednesday, July 31st. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research note on Friday. Finally, Stephens reiterated an "overweight" rating and set a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th.

Insiders Place Their Bets

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Repligen

A number of institutional investors have recently made changes to their positions in RGEN. Andra AP fonden bought a new stake in shares of Repligen in the 2nd quarter valued at approximately $25,000. International Assets Investment Management LLC acquired a new position in Repligen during the 2nd quarter valued at approximately $33,000. UMB Bank n.a. boosted its position in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 130 shares during the period. Lazard Asset Management LLC boosted its position in Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 136 shares during the period. Finally, Blue Trust Inc. boosted its position in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 127 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Up 0.6 %

Shares of NASDAQ:RGEN opened at $142.58 on Friday. The stock's 50-day moving average price is $140.26 and its two-hundred day moving average price is $143.44. The company has a current ratio of 10.44, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $113.50 and a 12-month high of $211.13. The firm has a market cap of $7.99 billion, a price-to-earnings ratio of -385.34, a PEG ratio of 4.27 and a beta of 0.96.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same period last year, the company earned $0.23 EPS. The firm's quarterly revenue was up 9.7% on a year-over-year basis. On average, research analysts forecast that Repligen will post 1.52 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.